Oncology – Gynecologic
RCT: Atezolizumab with Chemotherapy Extends Progression-Free Survival in dMMR Advanced Endometrial Cancer – Lancet Oncol
18 Aug, 2024 | 18:27h | UTCStudy Design and Population: The AtTEnd trial is a randomized, double-blind, placebo-controlled phase 3 study conducted in 89 hospitals across 11 countries. It enrolled 551 patients with advanced or recurrent endometrial carcinoma or carcinosarcoma, all of whom had not received prior systemic chemotherapy for recurrence.
Main Findings: The addition of atezolizumab to chemotherapy was associated with an improvement in progression-free survival, particularly in patients with mismatch repair-deficient (dMMR) tumors. In the overall population, progression-free survival and overall survival also showed positive trends.
Implications for Practice: The study suggests that atezolizumab may offer benefits when added to standard chemotherapy in patients with dMMR advanced or recurrent endometrial carcinoma, warranting further investigation as a potential first-line treatment option.
RCT: Radiation therapy alone superior to chemoradiation in low-grade localized endometrial cancer recurrences
1 May, 2024 | 21:41h | UTCThis randomized clinical trial assessed the effectiveness of radiation therapy alone versus concurrent chemoradiation in treating localized recurrences of endometrial cancer. Conducted from February 2008 to August 2020, the study involved 165 patients who were randomized to receive either radiation therapy alone or chemoradiation with weekly cisplatin. Findings indicate that radiation therapy alone resulted in longer progression-free survival (PFS) compared to chemoradiation, with a median PFS not reached for radiation alone versus 73 months for chemoradiation. Additionally, radiation therapy demonstrated lower rates of acute toxicity. The study concluded that for patients with low-grade and primarily vaginal recurrences, radiation therapy alone is the preferable treatment option, offering excellent outcomes without the added toxicity of chemotherapy.
Reference (link to abstract – $ for full-text):
Systematic Review | Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
8 Aug, 2023 | 13:11h | UTCPegylated liposomal doxorubicin for relapsed epithelial ovarian cancer – Cochrane Library
RCT | Niraparib after first-line platinum-based chemotherapy extends PFS vs. placebo in newly diagnosed advanced ovarian cancer
31 Jul, 2023 | 13:58h | UTCSee also: Visual Abstract
Commentary: Niraparib Maintenance in Newly Diagnosed Advanced Ovarian Cancer – The ASCO Post
Review | Radiomics-based fertility-sparing treatment in endometrial carcinoma
24 Jul, 2023 | 13:00h | UTC
FIGO staging of endometrial cancer: 2023
29 Jun, 2023 | 13:53h | UTCFIGO staging of endometrial cancer: 2023 – Gynecology & Obstetrics
#ASCO23 – RCT | Simple hysterectomy shown non-inferior to radical hysterectomy in low-risk early-stage cervical cancer
5 Jun, 2023 | 13:43h | UTCCommentaries:
Clinical Trial Update | Olaparib plus bevacizumab first-line maintenance in ovarian cancer
5 Jun, 2023 | 13:07h | UTCOriginal Study: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer – New England Journal of Medicine
Clinical Trial Update | Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer
15 May, 2023 | 12:43h | UTCOriginal Article: Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer – New England Journal of Medicine
Enhanced recovery after surgery (ERAS) society guidelines for gynecologic oncology: addressing implementation challenges
5 May, 2023 | 14:53h | UTC
Review | Cancer treatment-related cardiovascular toxicity in gynecologic malignancies
26 Apr, 2023 | 14:14h | UTC
Commentary on Twitter
A comprehensive #JACCCardioOnc state-of-the-art review of cancer treatment-related cardiovascular toxicity in gynecologic malignancies: https://t.co/24sFcHfyPf#GynOnc #GynCSM #CardioOnc #cardiotoxicity #CardioTwitter @emorywomenheart @sdent_duke pic.twitter.com/kzqILRzuwz
— JACC Journals (@JACCJournals) April 20, 2023
RCT | Intraperitoneal carboplatin achieves modest PFS gains in advanced ovarian cancer
25 Apr, 2023 | 14:24h | UTCIntraperitoneal Carboplatin for Ovarian Cancer — A Phase 2/3 Trial – NEJM Evidence
Commentary on Twitter
“In the first-line treatment of advanced epithelial ovarian cancer, intraperitoneal carboplatin resulted in a modest prolongation of PFS [progression-free survival] when given with dose-dense weekly paclitaxel regardless of residual tumor size….”#MedTwitter #ClinicalTrials
— NEJM Evidence (@NEJMEvidence) April 23, 2023
SR | Angiogenesis inhibitors for the treatment of epithelial ovarian cancer
25 Apr, 2023 | 14:22h | UTCAngiogenesis inhibitors for the treatment of epithelial ovarian cancer – Cochrane Library
M-A | Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer
17 Apr, 2023 | 12:59h | UTC
Review | Comprehensive care of women with genetic predisposition to breast and ovarian cancer
5 Apr, 2023 | 13:32h | UTC
RCT | Pembrolizumab plus chemotherapy in advanced endometrial cancer
3 Apr, 2023 | 13:48h | UTCPembrolizumab plus Chemotherapy in Advanced Endometrial Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Original Article: Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer https://t.co/dTyV1zTO0I
#SGOMtg @SGO_org pic.twitter.com/R3FDom8pVY— NEJM (@NEJM) March 29, 2023
RCT | Dostarlimab for primary advanced or recurrent endometrial cancer
3 Apr, 2023 | 13:46h | UTCDostarlimab for Primary Advanced or Recurrent Endometrial Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary:
Dostarlimab Plus Chemotherapy Elicits PFS Benefit in Recurrent Endometrial Cancer – OncLive
Consensus Statement | Management of vaginal intraepithelial neoplasia
28 Mar, 2023 | 14:37h | UTC
Cohort Study | Risk of endometrial polyps, hyperplasia, carcinoma, and uterine cancer after tamoxifen treatment in premenopausal women with breast cancer
2 Mar, 2023 | 12:56h | UTCCommentary: Risk of Uterine Diseases, Cancers Up With Tamoxifen Treatment – HealthDay
Commentary on Twitter
Use of tamoxifen as an adjuvant hormone therapy for breast cancer was associated with an increased risk of endometrial polyps, hyperplasia, carcinoma, and other uterine cancers in Korean premenopausal women. https://t.co/JqnKjemjoW
— JAMA Network Open (@JAMANetworkOpen) November 29, 2022
Recent advances in the classification of gynecological tract tumors: updates from the 5th edition of the WHO “Blue Book”
16 Feb, 2023 | 14:35h | UTC
M-A | Risk of endometrial cancer in postmenopausal women in relation to ultrasonographic endometrial thickness
8 Feb, 2023 | 12:21h | UTCRisk of endometrial cancer in asymptomatic postmenopausal women in relation to ultrasonographic endometrial thickness: systematic review and diagnostic test accuracy meta-analysis – American Journal of Obstetrics & Gynecology (link to abstract – $ for full-text)
Commentary on Twitter
AJOG Systematic Review: Risk of endometrial cancer in asymptomatic postmenopausal women in relation to ultrasonographic endometrial thickness: systematic review and diagnostic test accuracy meta-analysis https://t.co/uxPx8Jr160 pic.twitter.com/LugkrnKmjr
— AJOG (@AJOG_thegray) December 30, 2022
Diagnostic Study | Usefulness of CT radiomics in differentiating histologic subtypes of epithelial ovarian carcinoma
27 Jan, 2023 | 12:01h | UTC
Commentary on Twitter
Radiomic features extracted from contrast-enhanced CT scans were useful in the classification of histologic subtypes in epithelial ovarian carcinoma, high-grade serous carcinoma (HGSC) and non-HGSC. https://t.co/DBAXnl9r0X #OAResearch
— JAMA Network Open (@JAMANetworkOpen) December 6, 2022
Meta-analysis reaffirms benefits of O-RADS MRI for diagnosing indeterminate adnexal lesions
24 Jan, 2023 | 14:05h | UTCOriginal Study: O-RADS MRI: A Systematic Review and Meta-Analysis of Diagnostic Performance and Category-wise Malignancy Rates – Radiology (link to abstract – $ for full-text)
Commentary on Twitter
A meta-analysis of 4520 adnexal lesions from 12 studies showed that MRI O-RADS has a 92% summary sensitivity and a 91% summary specificity in characterizing lesions that are indeterminate at US. https://t.co/WSJVQUiM4T pic.twitter.com/kssAK2s02N
— Radiology (@radiology_rsna) November 23, 2022
Review | Advances in the diagnosis and early management of gestational trophoblastic disease
19 Jan, 2023 | 14:08h | UTCAdvances in the diagnosis and early management of gestational trophoblastic disease – BMJ Medicine
Review | Human papillomavirus vaccination and cervical cancer risk.
16 Dec, 2022 | 13:26h | UTCHuman papillomavirus vaccination and cervical cancer risk – The BMJ